Project Grant R01HL176637
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $801K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536 to Rhode Island Hospital to conduct research on pulmonary arterial hypertension (PAH). The goal is to characterize endothelial cell (EC) dysfunction in PAH, with a focus on understanding the role of anoikis resistance - abnormal programmed cell death triggered by cell detachment from the vessel wall. The research will leverage a "cell...
- This $171,858 Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a study titled "Computed Tomography for Early Detection and Phenotyping of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease with Implications for Treatment." The study aims to: Identify and validate quantitative CT imaging features for early detection of COPD-related pulmonary hypertension (COPD-PH). Apply advanced...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at Brigham & Women's Hospital Inc. to better understand changes in the pulmonary vasculature and their relationship to lung parenchyma using advanced CT imaging in patients with pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The $812,189 award, with a project period from May 1, 2025 to...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to investigate the role of the kynurenine pathway metabolism in pulmonary arterial hypertension (PAH). The $514,484 award to The Johns Hopkins University will fund a 5-year research project to establish a prospective observational cohort of PAH patients and measure longitudinal changes in kynurenine pathway metabolites and...
- The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...
- This $193,896 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify clinical markers that can serve as surrogates for right ventricular-pulmonary artery (RV-PA) coupling, a metric that quantifies right ventricular adaptation in pulmonary arterial hypertension (PAH). The grantee, The Johns Hopkins University, will leverage a unique dataset of over 100 PAH patients to 1) develop a multivariable model...